Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) Operating Expenses (2018 - 2025)

Eton Pharmaceuticals' Operating Expenses history spans 7 years, with the latest figure at $10.6 million for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 81.91% to $10.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $43.6 million, a 67.58% increase, with the full-year FY2025 number at $43.6 million, up 67.58% from a year prior.
  • Operating Expenses hit $10.6 million in Q4 2025 for Eton Pharmaceuticals, up from $9.2 million in the prior quarter.
  • Over the last five years, Operating Expenses for ETON hit a ceiling of $13.4 million in Q2 2025 and a floor of $4.4 million in Q4 2021.
  • Historically, Operating Expenses has averaged $6.7 million across 5 years, with a median of $5.8 million in 2024.
  • Biggest five-year swings in Operating Expenses: crashed 44.31% in 2021 and later skyrocketed 81.91% in 2025.
  • Tracing ETON's Operating Expenses over 5 years: stood at $4.4 million in 2021, then grew by 20.22% to $5.3 million in 2022, then rose by 6.13% to $5.6 million in 2023, then grew by 3.98% to $5.8 million in 2024, then skyrocketed by 81.91% to $10.6 million in 2025.
  • Business Quant data shows Operating Expenses for ETON at $10.6 million in Q4 2025, $9.2 million in Q3 2025, and $13.4 million in Q2 2025.